Feng Huihao, Cheng Xiaoming, Zeng Feng
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Dec;29(24):2188-90.
Thyroid carcinoma is the most common endocrine maligancy, and the worldwide incidence has been rising in recent years. Differentiated thyroid carcinoma is the most common thyroid malignancy, which include thyroid papillary carcinoma and follicular thyroid carcinoma, accounting for about 90 percent of thyroid carcinoma incidence. Currently, surgical treatment, iodine radiotherapy and TSH suppressive therapy are the commonly accepted effective treatments for differentiated thyroid carcinoma, and most patients can be cured. But there are still some patients not sensitive to the general treatments, who have lost the treatment of opportunity. Molecular targeted therapy is an agonistic or suppressive treatment for molecular biology targets of malignant tumor, and currently is a frontier research in the field of malignancy treatment. By retrieving and analyzing the related literature of molecular targeted therapy of thyroid carcinoma through PUBMED in the past 5 years, the article introduced the current status of molecular targeted therapy of thyroid carcinoma.
甲状腺癌是最常见的内分泌恶性肿瘤，近年来全球发病率一直在上升。分化型甲状腺癌是最常见的甲状腺恶性肿瘤，包括甲状腺乳头状癌和滤泡状甲状腺癌，约占甲状腺癌发病率的90%。目前，手术治疗、碘放疗和促甲状腺激素抑制治疗是公认的分化型甲状腺癌有效治疗方法，大多数患者可以治愈。但仍有一些患者对常规治疗不敏感，失去了治疗机会。分子靶向治疗是针对恶性肿瘤分子生物学靶点的激动或抑制性治疗，目前是恶性肿瘤治疗领域的前沿研究。通过检索和分析过去5年在PUBMED上关于甲状腺癌分子靶向治疗的相关文献，本文介绍了甲状腺癌分子靶向治疗的现状。
